Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R & D, Johnson & Johnson
NEW BRUNSWICK, N.J., Aug. 8, 2022 - Johnson & Johnson (NYSE: JNJ) (“the Company”) announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, and the Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson’s industry-leading portfolio. The Compa...
Source: Johnson and Johnson - August 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
European Commission Approves IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep ...
Source: Johnson and Johnson - August 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference
New Brunswick, NJ (August 2nd, 2022) -- Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com. A webcast and podcast replay will be available approximately 48 hours after the live webcast. ### (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 2, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI ® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
BEERSE, Belgium, 22 July 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation (CMA) for TECVAYLI® (teclistamab) as monotherapy for adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. Teclistamab is an off-the-shelf, T-cell r...
Source: Johnson and Johnson - July 22, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS
expand
...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2022
New Brunswick, N.J. (July 18, 2022) – Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2022 of $1.13 per share on the company’s common stock. The dividend is payable on September 6, 2022 to shareholders of record at the close of business on August 23, 2022. The ex-dividend date is August 22, 2022. About Johnson & JohnsonAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage ...
Source: Johnson and Johnson - July 18, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson ’s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022
NEW BRUNSWICK, N.J., July 18, 2022 -- Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization’s Board of Directors and partnered with four company CEOs to shape and grow Johnson & Johnson into the most broadly based healthcare company in the world.He will be succeeded in this role by Elizabeth (Liz) Forminard, a strong Credo-based leader who has had an exce...
Source: Johnson and Johnson - July 18, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 29, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Talquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple myeloma cells and CD3 o...
Source: Johnson and Johnson - June 29, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Receives Positive CHMP Opinion for IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, June 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a new treatment option with IMBRUVICA® (ibrutinib) in an oral fixed-duration combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). Outcomes for patients with CLL have improved in the last decade with the advent of oral therapies that target the underlying disease biology.[1] This provides the opportunity...
Source: Johnson and Johnson - June 24, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Renews Commitment to Fight Neglected Tropical Diseases, Investing in Beating Intestinal Worms, Dengue and Leprosy
NEW BRUNSWICK, N.J., June 23, 2022 – Johnson & Johnson proudly joined the global community, including governments, foundations, non-profit organizations and other pharmaceutical companies, to endorse the Kigali Declaration on Neglected Tropical Diseases. Together, we are recommitting to our long-established efforts to control and eliminate neglected tropical diseases (NTDs), a set of debilitating diseases that put at risk the health of 1.7 billion people around the world, especially the most vulnerable and underserved.Working from the lab to the last-mile of health delivery, Johnson & Johnson is today committing ...
Source: Johnson and Johnson - June 23, 2022 Category: Pharmaceuticals Tags: Health & amp; Wellness Source Type: news
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
SINGAPORE, June 21, 2022 – Johnson & Johnson (the Company) today announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) at Singapore’s Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse. As the first of the J&J Centers for Global Health Discovery (J&J Centers) in the Asia-Pacific region, the Satellite Center at Duke-NUS aims to help drive new solutions to address flaviviruses, which disproportionately impact communities across the region, by ...
Source: Johnson and Johnson - June 21, 2022 Category: Pharmaceuticals Source Type: news
Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees
NEW BRUNSWICK, N.J., June 14, 2022 – After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity Innovation Challenge. The awardees, who possess lived experience and a deep understanding of the communities they serve, were selected for their work in generating solutions to help close racial health and mortality gaps in six cities where Black and Brown individuals experience significant health inequities: Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia.The Health Equity Innovation Challenge was created by J...
Source: Johnson and Johnson - June 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
